Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis - 30/10/07
, Zahir Amoura a, Guy Aymard b, Sylvain Choquet c, Salim Trad a, Bénédicte Lebrun Vignes b, Jean-Sébastien Hulot a, Francis Berenbaum e, Philippe Lechat b, Patrice Cacoub a, Annick Ankri d, Xavier Mariette f, Véronique Leblond c, Jean-Charles Piette a
Corresponding author. Tel.: +33 1 4217 8248; fax: +33 1 4217 8033.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
Patients with primary systemic (AL) amyloidosis or multiple myeloma are frequently treated with cyclic dexamethasone (DXM) courses and often require oral anticoagulants. We previously reported a strong potentiation of oral anticoagulants with intravenous methylprednisolone and observed a similar potentiation with DXM in 3 patients, which led us to prospectively investigate the interaction between DXM and oral anticoagulants.
Methods |
Nine patients with multiple myeloma (n=6) or AL amyloidosis (n=3), including 6 prospective patients, taking fluindione (n=8) or warfarin (n=1), were studied for a total of 10 cycles. DXM (40mg/day for 4days every 28days) was administered alone (n=4) or with melphalan (n=5). One patient was studied for 2 consecutive cycles after a moderate increase in the international normalized ratio (INR) during the first course of DXM. International normalized ratio (INR) was measured serially during DXM administration. Plasma oral anticoagulant concentrations were measured for 5 cycles.
Results |
The mean INR increased from 2.75 (range: 1.80-3.6) at baseline to 5.22 (3.09-7.07) after DXM. Oral anticoagulants were transiently stopped during 8 cycles and 1mg oral vitamin K was given during 2. No serious bleeding was observed. Plasma oral anticoagulant concentrations increased after DXM administration. In controls receiving DXM without oral anticoagulants, DXM alone did not increase prothrombin time.
Conclusion |
High dose DXM can potentiate oral anticoagulants and elevate INR substantially. INR should therefore be monitored repeatedly during concomitant administration of these 2 drugs to allow individual adaptation of oral anticoagulant doses.
Le texte complet de cet article est disponible en PDF.Keywords : Oral anticoagulants, Dexamethasone, Fluindione, Warfarin, Drug interactions, Multiple myeloma, Amyloidosis
Plan
 | The results of this study have been reported in the congress of Société Française de Rhumatologie (Paris, 2005). |
Vol 74 - N° 5
P. 446-452 - octobre 2007 Retour au numéro
Article précédent
- The ESPOIR cohort: A ten-year follow-up of early arthritis in France : Methodology and baseline characteristics of the 813 included patients
- Bernard Combe, Joëlle Benessiano, Francis Berenbaum, Alain Cantagrel, Jean-Pierre Daurès, Maxime Dougados, Patrice Fardellone, Bruno Fautrel, Réné-Marc Flipo, Philippe Goupille, Francis Guillemin, Xavier Le Loet, Isabelle Logeart, Xavier Mariette, Olvier Meyer, Philippe Ravaud, Nathalie Rincheval, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia
- Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: The MESSAGE study
- Bernard Mazières, Hervé Bard, Marie Ligier, Isabelle Bru, Geneviève Giret d'Orsay, Claude Le Pen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?